Artios Pharma recently secured $115 million in a Series D growth round, with substantial backing from US investors. This round was co-led by SV Health Investors in Boston, US, and London, UK, alongside new investor RA Capital Management from Boston, New York, and San Francisco, with the addition of Janus Henderson Investors. The funding also saw strong support from Artios’ existing investors, highlighting the confidence in the company’s innovative approach to cancer therapeutics.
The primary goal of the Series D funding is to advance the clinical evaluation of Artios’ lead program, alnodesertib. This includes enrolling additional ATM-negative patients in second-line pancreatic cancer and third-line colorectal cancer. Notably, the program received Fast Track Designation from the U.S. FDA, emphasizing its potential impact in addressing critical unmet medical needs in oncology.
During the AACR meeting in April 2025, Artios presented compelling data on alnodesertib in combination with low-dose irinotecan. The study showcased a remarkable 50% confirmed overall response rate in patients with ATM-negative solid tumors, underscoring the program’s efficacy and potential clinical benefits. This success is particularly significant as there are currently no approved therapies tailored to patients with ATM-deficiency, a population that has shown durable responses to alnodesertib across various solid tumors.
Apart from advancing alnodesertib, the Series D proceeds will also support the initiation of a Phase 2 randomized clinical trial for ART6043, Artios’ second promising candidate. This molecule targets BRCA-mutant HER2-negative breast cancer patients eligible for PARP inhibitor treatment. Early data on ART6043, a DNA polymerase Theta inhibitor, exhibited a favorable tolerability profile, anticipated pharmacokinetic/pharmacodynamic activity, and promising clinical signals, setting the stage for further development in this patient population.
In addition to these key programs, Artios is actively progressing a first-in-class DDR inhibitor-Antibody Drug Conjugate (DDRi-ADC) program. The company is poised to name a lead candidate in Q1 2026, underscoring its commitment to advancing innovative therapeutic modalities in the field of DNA damage response. By expanding its portfolio and pipeline, Artios aims to address critical unmet needs in cancer care, with a focus on indications such as pancreatic, colorectal, and breast cancers, where survival rates are often limited.
Mike Andriole, the CEO of Artios Pharma, expressed his enthusiasm about the Series D funding, emphasizing its role in accelerating the path to potential registration for both alnodesertib and ART6043. He highlighted the importance of broadening development efforts to cater to patients with high unmet medical needs, particularly in challenging-to-treat cancers. Andriole extended his gratitude to both existing and new investors for their support and shared commitment to bringing innovative medicines to patients expeditiously.
The diverse group of investors supporting the Series D round reflects the confidence in Artios Pharma’s vision and potential impact in the oncology landscape. Notable investors include Andera Partners, Avidity Partners, EQT Life Sciences, Novartis Venture Fund, Pfizer Ventures, and Sofinnova Partners, among others. Their collective support not only validates the company’s progress but also underscores the significance of advancing novel approaches in cancer therapeutics for improved patient outcomes.
Artios Pharma’s focus on pioneering DNA damage response therapeutics signals a paradigm shift in cancer treatment, offering new hope for patients facing challenging diagnoses. With a robust pipeline and a strategic approach to addressing critical unmet needs, the company is poised to make significant contributions to the field of oncology. The recent Series D funding marks a crucial milestone in advancing innovative treatments and underscores the collective effort to transform the future of cancer care.
Takeaways:
– Artios Pharma secures $115 million in a Series D funding round to advance innovative cancer therapeutics targeting critical unmet needs.
– The funding will support the clinical evaluation of alnodesertib and the initiation of a Phase 2 trial for ART6043, addressing ATM-negative and BRCA-mutant HER2-negative breast cancer patients, respectively.
– Artios’ focus on DDR inhibitors and ADC programs highlights its commitment to developing next-generation cancer treatments with the potential to revolutionize patient care.
Read more on <a href=”https://Artios Pharma recently secured $115 million in a Series D growth round, with substantial backing from US investors. This round was co-led by SV Health Investors in Boston, US, and London, UK, alongside new investor RA Capital Management from Boston, New York, and San Francisco, with the addition of Janus Henderson Investors. The funding also saw strong support from Artios’ existing investors, highlighting the confidence in the company’s innovative approach to cancer therapeutics.
The primary goal of the Series D funding is to advance the clinical evaluation of Artios’ lead program, alnodesertib. This includes enrolling additional ATM-negative patients in second-line pancreatic cancer and third-line colorectal cancer. Notably, the program received Fast Track Designation from the U.S. FDA, emphasizing its potential impact in addressing critical unmet medical needs in oncology.
During the AACR meeting in April 2025, Artios presented compelling data on alnodesertib in combination with low-dose irinotecan. The study showcased a remarkable 50% confirmed overall response rate in patients with ATM-negative solid tumors, underscoring the program’s efficacy and potential clinical benefits. This success is particularly significant as there are currently no approved therapies tailored to patients with ATM-deficiency, a population that has shown durable responses to alnodesertib across various solid tumors.
Apart from advancing alnodesertib, the Series D proceeds will also support the initiation of a Phase 2 randomized clinical trial for ART6043, Artios’ second promising candidate. This molecule targets BRCA-mutant HER2-negative breast cancer patients eligible for PARP inhibitor treatment. Early data on ART6043, a DNA polymerase Theta inhibitor, exhibited a favorable tolerability profile, anticipated pharmacokinetic/pharmacodynamic activity, and promising clinical signals, setting the stage for further development in this patient population.
In addition to these key programs, Artios is actively progressing a first-in-class DDR inhibitor-Antibody Drug Conjugate (DDRi-ADC) program. The company is poised to name a lead candidate in Q1 2026, underscoring its commitment to advancing innovative therapeutic modalities in the field of DNA damage response. By expanding its portfolio and pipeline, Artios aims to address critical unmet needs in cancer care, with a focus on indications such as pancreatic, colorectal, and breast cancers, where survival rates are often limited.
Mike Andriole, the CEO of Artios Pharma, expressed his enthusiasm about the Series D funding, emphasizing its role in accelerating the path to potential registration for both alnodesertib and ART6043. He highlighted the importance of broadening development efforts to cater to patients with high unmet medical needs, particularly in challenging-to-treat cancers. Andriole extended his gratitude to both existing and new investors for their support and shared commitment to bringing innovative medicines to patients expeditiously.
The diverse group of investors supporting the Series D round reflects the confidence in Artios Pharma’s vision and potential impact in the oncology landscape. Notable investors include Andera Partners, Avidity Partners, EQT Life Sciences, Novartis Venture Fund, Pfizer Ventures, and Sofinnova Partners, among others. Their collective support not only validates the company’s progress but also underscores the significance of advancing novel approaches in cancer therapeutics for improved patient outcomes.
Artios Pharma’s focus on pioneering DNA damage response therapeutics signals a paradigm shift in cancer treatment, offering new hope for patients facing challenging diagnoses. With a robust pipeline and a strategic approach to addressing critical unmet needs, the company is poised to make significant contributions to the field of oncology. The recent Series D funding marks a crucial milestone in advancing innovative treatments and underscores the collective effort to transform the future of cancer care.
Takeaways:
– Artios Pharma secures $115 million in a Series D funding round to advance innovative cancer therapeutics targeting critical unmet needs.
– The funding will support the clinical evaluation of alnodesertib and the initiation of a Phase 2 trial for ART6043, addressing ATM-negative and BRCA-mutant HER2-negative breast cancer patients, respectively.
– Artios’ focus on DDR inhibitors and ADC programs highlights its commitment to developing next-generation cancer treatments with the potential to revolutionize patient care.” target=”_blank” rel=”noopener”>Artios Pharma recently secured $115 million in a Series D growth round, with substantial backing from US investors. This round was co-led by SV Health Investors in Boston, US, and London, UK, alongside new investor RA Capital Management from Boston, New York, and San Francisco, with the addition of Janus Henderson Investors. The funding also saw strong support from Artios’ existing investors, highlighting the confidence in the company’s innovative approach to cancer therapeutics.The primary goal of the Series D funding is to advance the clinical evaluation of Artios’ lead program, alnodesertib. This includes enrolling additional ATM-negative patients in second-line pancreatic cancer and third-line colorectal cancer. Notably, the program received Fast Track Designation from the U.S. FDA, emphasizing its potential impact in addressing critical unmet medical needs in oncology.During the AACR meeting in April 2025, Artios presented compelling data on alnodesertib in combination with low-dose irinotecan. The study showcased a remarkable 50% confirmed overall response rate in patients with ATM-negative solid tumors, underscoring the program’s efficacy and potential clinical benefits. This success is particularly significant as there are currently no approved therapies tailored to patients with ATM-deficiency, a population that has shown durable responses to alnodesertib across various solid tumors.Apart from advancing alnodesertib, the Series D proceeds will also support the initiation of a Phase 2 randomized clinical trial for ART6043, Artios’ second promising candidate. This molecule targets BRCA-mutant HER2-negative breast cancer patients eligible for PARP inhibitor treatment. Early data on ART6043, a DNA polymerase Theta inhibitor, exhibited a favorable tolerability profile, anticipated pharmacokinetic